Cencora, Inc. (COR)
Automate Your Wheel Strategy on COR
With Tiblio's Option Bot, you can configure your own wheel strategy including COR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol COR
- Rev/Share 1633.9741
- Book/Share 11.4033
- PB 29.0594
- Debt/Equity 4.1615
- CurrentRatio 0.9047
- ROIC 0.1274
- MktCap 57568194540.0
- FreeCF/Share 5.8907
- PFCF 50.4281
- PE 30.3297
- Debt/Assets 0.1114
- DivYield 0.0074
- ROE 1.9632
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | COR | Wells Fargo | Equal Weight | Overweight | -- | $337 | June 3, 2025 |
| Resumed | COR | Mizuho | -- | Outperform | -- | $280 | Dec. 4, 2024 |
| Downgrade | COR | BofA Securities | Buy | Neutral | $275 | $245 | Sept. 18, 2024 |
News
Cencora, Inc. (COR) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Published: September 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Cencora, Inc. (NYSE:COR ) Wells Fargo 20th Annual Healthcare Conference 2025 September 5, 2025 8:45 AM EDT Company Participants James Cleary - Executive VP & CFO Bennett Murphy - Senior VP, Head of Investor Relations & Treasury Conference Call Participants Stephen Baxter - Wells Fargo Securities, LLC, Research Division Presentation Stephen Baxter Senior Equity Analyst All right. Good morning, everyone.
Read More
Here's Why You Should Hold Cencora Stock in Your Portfolio Now
Published: September 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
COR gains from strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose risks.
Read More
COR vs. MEDP: Which Stock Is the Better Value Option?
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical Services stocks have likely encountered both Cencora (COR) and Medpace (MEDP). But which of these two stocks is more attractive to value investors?
Read More
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. GE, HWM, COR and CAKE are some such stocks.
Read More
Cencora (COR) is an Incredible Growth Stock: 3 Reasons Why
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Why Cencora (COR) is a Top Value Stock for the Long-Term
Published: August 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap
Published: August 12, 2025 by: Seeking Alpha
Sentiment: Positive
Cencora delivered strong quarterly results and guidance upgrades, but expectations need to be moderated as these results should fade in the coming quarters. The valuation remains elevated at 17.9x forward P/E, well above the 5-year average, making the risk/reward unattractive at current levels. Key risks include heavy revenue exposure to Walgreens Boots Alliance, which faces solvency issues and plans to sell its COR stake.
Read More
3 Reasons Growth Investors Will Love Cencora (COR)
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Cencora, Inc. (NYSE:COR ) Q3 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Bennett S. Murphy - Senior VP, Head of Investor Relations & Treasury James F.
Read More
COR Q3 Earnings & Revenues Beat Estimates, '25 EPS View Raised
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora posts strong Q3 results with earnings and revenues surpassing estimates; raises FY25 EPS guidance on robust U.S. segment growth.
Read More
Cencora (COR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Can Specialty and GLP-1 Momentum Support Cencora's Q3 Results?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
COR benefits from strong specialty and GLP-1 demand, but Q3 results may face pressure from international weakness.
Read More
Gear Up for Cencora (COR) Q3 Earnings: Wall Street Estimates for Key Metrics
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Beyond analysts' top-and-bottom-line estimates for Cencora (COR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Read More
Cencora (COR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Here's Why You Should Add Cencora Stock to Your Portfolio Now
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
COR gains on strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose ongoing risks.
Read More
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Cencora (COR) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Read More
Here's Why You Should Add Cencora Stock to Your Portfolio Now
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Read More
Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs
Published: May 16, 2025 by: Seeking Alpha
Sentiment: Positive
Cencora gets a buy rating, agreeing with today's consensus from Wall St. The sector and macro environment points to continued demand for the healthcare supplies and niche specialty drugs Cencora can distribute. Future share price targets point to significant potential upside over 3 years, justifying a buy despite the stock trading above average now.
Read More
Here's Why Cencora (COR) is a Strong Momentum Stock
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
Cencora (COR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
COR's second-quarter fiscal 2025 results showcase a strong segmental performance. The company's earnings guidance for fiscal 2025 looks encouraging.
Read More
Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Cencora, Inc. (NYSE:COR ) Q2 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Bennett Murphy - Senior Vice President, Head of Investor Relations & Treasury Bob Mauch - President & Chief Executive Officer Jim Cleary - Executive Vice President & Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore ISI Michael Cherny - Leerink Capital Lisa Gill - JPMorgan George Hill - Deutsche Bank Charles Rhyee - TD Cowen Eric Percher - Nephron Research Steven Valiquette - Mizuho Securities Allen Lutz - Bank of America Daniel Grosslight - Citi Kevin Caliendo - UBS Erin Wright …
Read More
Cencora (COR) Beats Q2 Earnings and Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) came out with quarterly earnings of $4.42 per share, beating the Zacks Consensus Estimate of $4.08 per share. This compares to earnings of $3.80 per share a year ago.
Read More
Cencora Reports Fiscal 2025 Second Quarter Results
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below.
Read More
MedTech Stocks' Earnings to Watch on May 7: COR, QDEL & INGN
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
The medical device sector saw steady sales growth in the first quarter of 2025, supported by innovation in AI, wearables, and personalized care. However, earnings gains were more modest as global tariffs, inflationary costs, and supply chain disruptions continued to pressure margins.
Read More
Unveiling Cencora (COR) Q2 Outlook: Wall Street Estimates for Key Metrics
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Read More
Cencora (COR) Earnings Expected to Grow: Should You Buy?
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Cencora (COR) and Intensity Therapeutics Inc. (INTS) have performed compared to their sector so far this year.
Read More
About Cencora, Inc. (COR)
- IPO Date 1995-04-04
- Website https://www.amerisourcebergen.com
- Industry Medical - Distribution
- CEO Robert P. Mauch PharmD
- Employees 42000